["T'orsade de pointe" and amiodarone (author's transl)]

Area of Science:

• Cardiology
• Pharmacology
• Genetics

Background:

• Mitral valve disease can predispose patients to cardiac complications.
• Certain genetic conditions like microcytemia may influence drug metabolism and cardiac response.
• Amiodarone is a potent antiarrhythmic drug with known potential for serious adverse effects.

Observation:

• A patient with mitral valve disease and microcytemia developed jaundice.
• The patient was undergoing therapy with amiodarone for an unspecified condition.
• During amiodarone treatment, the patient exhibited a prolonged Q-T interval.

Findings:

• The prolonged Q-T interval progressed to torsade de pointe, a life-threatening arrhythmia.
• Irreducible ventricular fibrillation occurred, indicating a severe cardiac event.
• The adverse cardiac events were attributed to suboptimal amiodarone therapy management.

Implications:

• This case highlights the critical need for careful amiodarone dosage and monitoring, especially in patients with pre-existing cardiac conditions and potential drug interactions.
• Understanding the interplay between cardiac disease, genetic factors, and antiarrhythmic drug toxicity is crucial for patient safety.
• Further research into personalized antiarrhythmic drug therapy is warranted to mitigate risks in vulnerable patient populations.